COVID-19与代谢性疾病:机制与临床管理
综述指出高达50%的COVID-19死亡患者合并代谢与血管疾病,代谢功能障碍患者重症风险增加,SARS-CoV-2感染可能诱发新发糖尿病或加重原有代谢紊乱。文章更新了代谢内分泌疾病易感重症的机制、实用管理建议及COVID-19合并糖尿病的新治疗选择。
要点
- 代谢功能障碍患者(肥胖、高血压、NAFLD、糖尿病)重症COVID-19风险增加。
- SARS-CoV-2感染可能导致新发糖尿病或加重原有代谢紊乱。
- 综述更新了COVID-19合并糖尿病患者的治疗选择与临床管理挑战。
核心结论
- 代谢与内分泌系统与COVID-19存在多重直接联系,代谢功能障碍患者重症风险增加,感染可能诱发新发糖尿病或加重代谢紊乱。
研究设计与样本
- 综述,总结COVID-19与代谢性疾病相互作用的机制、临床管理建议及治疗选择。
主要发现
- 高达50%的COVID-19死亡患者合并代谢与血管疾病。
- 肥胖、高血压、非酒精性脂肪肝病和糖尿病患者发生重症COVID-19的风险增加。
- SARS-CoV-2感染可能导致新发糖尿病或加重既有的代谢紊乱。
临床怎么用
- 综述更新了COVID-19大流行期间及后疫情时代代谢疾病患者的实用管理建议。
- 总结了COVID-19合并糖尿病患者的新的治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Up to 50% of the people who have died from COVID-19 had metabolic and vascular disorders. Notably, there are many direct links between COVID-19 and the metabolic and endocrine systems. Thus, not only are patients with metabolic dysfunction (eg, obesity, hypertension, non-alcoholic fatty liver disease, and diabetes) at an increased risk of developing severe COVID-19 but also infection with SARS-CoV-2 might lead to new-onset diabetes or aggravation of pre-existing metabolic disorders. In this Review, we provide an update on the mechanisms of how metabolic and endocrine disorders might predispose patients to develop severe COVID-19. Additionally, we update the practical recommendations and management of patients with COVID-19 and post-pandemic. Furthermore, we summarise new treatment options for patients with both COVID-19 and diabetes, and highlight current challenges in clinical management.
引用
- Steenblock C, Schwarz PEH, Ludwig B, et al. COVID-19 and metabolic disease: mechanisms and clinical management. Lancet Diabetes Endocrinol. 2021. PMID: 34619105. doi:10.1016/S2213-8587(21)00244-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。